News by subject: Clinical Study

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company's Phase IIa clinical trial...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated...

- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete regression of one of three metastatic lesions in...

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral...

PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration ("FDA") for advancing KETARXtm (ketamine) towards Phase 3...

In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least a 0.5% reduction in A1c, and 56% achieved at least...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's Phase I/II...

Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early...

BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, in its March 17, 2023 issue, Medical...

Organovo Holdings, Inc. , a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today...

Psyence Group Inc , a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that its newly incorporated wholly owned Australian subsidiary, Psyence Australia Pty Ltd, has...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

Arbutus Biopharma Corporation ("Arbutus"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first subject has been...

- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology - - Additional poster reports preclinical profile...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02...

Curium, a world leader in nuclear medicine, confirmed today that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company's ECLIPSE Phase 3 clinical trial (NCT05204927) ongoing in the USA, France, Spain, and...

SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world's largest prospective studies. The SomaLogic team...

ResMed announced today the...

BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that findings from a study on its lead...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today an update on the...

Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA modality for the treatment of Amyotrophic Lateral Sclerosis (ALS). "The FDA's decision to grant...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the...

Sirona Biochem Corp. ("Sirona") is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology ("ICGEB") to advance Sirona's antiviral library of compounds....

Theralase® Technologies Inc. ("Theralase®" or the "Company") , a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely...

Theratechnologies Inc. ("Theratechnologies" or the "Company") ...

Algernon Pharmaceuticals Inc.  (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in...

Nymox Pharmaceutical Corporation (the "Company") is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today confirms that the first subject has been dosed in a Phase I study...

ENA Respiratory, a...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies and Pantherna Therapeutics GmbH ("Pantherna"), a biopharmaceutical company developing advanced...

Optimi Health Corp. (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and...

Microbix Biosystems Inc. , a life sciences innovator, manufacturer, and exporter, announces that it will be presenting results of its collaboration with the Microbiology Laboratory of the Queen Elizabeth Hospital of Health PEI ("Health PEI"), in...

Theralase® Technologies Inc. ("Theralase®" or the "Company") , a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely...

Theralase® Technologies Inc. ("Theralase®" or the "Company") , a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely...

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant -7.4 point difference between SPL026...

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I clinical study for Skye Bioscience, Inc.'s (SKYE: OTCQB) proprietary, synthetic cannabinoid derivative,...

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce positive topline results from the XRX-OXY-101 ?...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company's follow-on study designed to build on...

Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and...

Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD) School of Medicine,...

Reunion Neuroscience Inc. ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that the Company has completed the...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 ("Ifenprodil") for...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration ("FDA")...